inactivated hepatitis A vaccine + measles, mumps, and rubella vaccine

This drug is a **combination vaccine regimen** consisting of an inactivated hepatitis A vaccine administered together with measles, mumps, and rubella (MMR) vaccine. The hepatitis A vaccine contains inactivated hepatitis A virus antigen, which stimulates an immune response providing protection against hepatitis A[1][3]. The MMR vaccine includes live attenuated strains of measles, mumps, and rubella viruses that induce protective immunity against the three diseases[2][3]. The combination regimen is typically administered to children aged 12 to 23 months and shown to be non-inferior in immunogenicity and safety compared to administration of each vaccine separately[1][3]. This approach is used to optimize the pediatric immunization schedule by providing protection against multiple diseases in a single visit[1][3]. Both vaccine components work through **active immunization** by stimulating adaptive immune responses through antigen presentation. The hepatitis A component is inactivated, while the MMR component is live attenuated[1][3]. Primary indications are prevention of hepatitis A, measles, mumps, and rubella in children.

Brand names

HavrixM-M-R II

Other names

inactivated hepatitis A vaccine + measles, mumps, and rubella vaccine